基本情報
- CAS
81525-10-2- 標準SMILES
N=C(N)c1ccc2cc(OC(=O)c3ccc(N=C(N)N)cc3)ccc2c1- InChIKey
MQQNFDZXWVTQEH-UHFFFAOYSA-N- 分子式
- C19H17N5O2
- 平均分子量
- 347.4 g/mol
- 単同位体質量
- 347.1382248
概要
Nafamostat is a member of benzoic acids and a member of guanidines.
名称と識別子
- 優先名称
- Nafamostat
- IUPAC
- (6-carbamimidoylnaphthalen-2-yl) 4-(diaminomethylideneamino)benzoate
- 現地名
- ナファモスタット
- 英語名
- Nafamostat
- 分子式
- C19H17N5O2
- 分子量
- 347.37
名称と別名
Nafamostat81525-10-2Nafamostatum6-Amidino2-naphthyl 4-guanidinobenzoateY25LQ0H97Dp-Guanidinobenzoic acid ester with 6-hydroxy-2-naphthamidineCKD3146-(Aminoiminomethyl)-2-naphthalenyl 4-((aminoiminomethyl)amino)benzoateBenzoic acid, 4-((aminoiminomethyl)amino)-, 6-(aminoiminomethyl)-2-naphthalenyl ester6-carbamimidoylnaphthalen-2-yl 4-((diaminomethylidene)amino)benzoate6-carbamimidoylnaphthalen-2-yl 4-[(diaminomethylidene)amino]benzoate6'-amidino-2-naphthyl 4-guanidinobenzoate
名称をさらに表示
4-グアニジノ安息香酸6-アミジノ-2-ナフチル4-[アミジノアミノ]安息香酸6-アミジノ-2-ナフチル4-(アミジノアミノ)安息香酸6-アミジノ-2-ナフチルナファムスタットナファモスタット4-[(アミノイミノメチル)アミノ]安息香酸6-(アミノイミノメチル)-2-ナフタレニル6-カルバムイミドイルナフタレン-2-イル 4-カルバムイミドアミドベンゾアートNAFAMOSTAT MESILATEFUT-175FUTHANNafamstatNaphthalmostatMesylate nafaMostatNafamostat (FUT-175)NafamostatMesilateBase
物性
構造計算による物性
- XLogP
- 2
- 極性表面積
- 141 Ų
- 水素結合供与体数
- 4
- 水素結合受容体数
- 4
- 回転可能結合数
- 5
- 重原子数
- 26
- 形式電荷
- 0
- 複雑度
- 552
実験および物理化学的性質
Drugs
Pharmaceutical
Pharmaceuticals -> Listed in ZINC15
物理化学的性質
- 沸点
- 586 · 586.0±60.0 °C(Predicted)
- 比重(密度)
- 1.39 · 1.39±0.1 g/cm3(Predicted)
- 貯蔵温度
- 2 · under inert gas (nitrogen or Argon) at 2–8 °C
- 溶解性
- Soluble in DMSO
- 外見
- Powder
- 酸解離定数(Pka)
- 11.3 · 11.30±0.30(Predicted)
安全と法規制
安全情報は参考情報です。供給元の安全データシート（SDS）、適用法令、専門家による評価に代わるものではありません。
毒性情報
Drug Induced Liver Injury
Drug-Induced Liver Injury Severity and Toxicity (DILIst)
Nafamostat
DILI Positive
DOI:10.1016/j.drudis.2019.09.022
化学と産業
薬理情報
Pharmacodynamics
Nafamostat is a fast-acting proteolytic inhibitor used during hemodialysis to prevent the proteolysis of fibrinogen into fibrin by competitively inhibiting several serine proteases including thrombin. It improves acute pancreatitis and prevents blood clot formation during extracorporeal circulation and has an anti-inflammatory effect in vitro. A study suggets that nafamostat has a neuroprotective role during ischemia-induced brain injury from antithrombin activity.
Mechanism of Action
Nafamostat mesilate inhibits various enzyme systems, such as coagulation and fibrinolytic systems (thrombin, Xa, and XIIa), the kallikrein–kinin system, the complement system, pancreatic proteases and activation of protease-activated receptors (PARs). Nafamostat inhibits lipopolysaccharide-induced nitric oxide production, apoptosis, and interleukin (IL)-6 and IL-8 levels in cultured human trophoblasts. It is shown to act as an antioxidant in TNF-α-induced ROS production.
Biological Half-LifeApproximately 8 minutes
Metabolism/MetabolitesNafamostat is mainly hydrolyzed by hepatic carboxyesterase and long-chain acyl-CoA hydrolase in human liver cytosol. Main metabolites are p-guanidinobenzoic acid (PGBA) and 6-amidino-2-naphthol (AN) as inactive protease inhibitors.
MeSH Pharmacological Classification
Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects.
Agents that prevent BLOOD CLOTTING.
Compounds which inhibit or antagonize biosynthesis or actions of proteases (ENDOPEPTIDASES).
Serine proteinase inhibitors which inhibit trypsin. They may be endogenous or exogenous compounds.
Exogenous or endogenous compounds which inhibit SERINE ENDOPEPTIDASES.
関連反応
0 件
現在のフィルター条件では反応記録がありません。
化合物ノート
読み込み中…